Eli Lilly secures Alimta patent win over Apotex
02-01-2020
Eli Lilly bids to stop generics cutting Alimta exclusivity
23-08-2013
Jonathan Weiss / Shutterstock.com
The US Court of Appeals for the Federal Circuit yesterday, December 21, upheld Eli Lilly’s success in barring the sale of a copycat version of cancer treatment Alimta (pemetrexed disodium).
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Eli, Lilly, Apotex, Alimta, patent, pemetrexed, disodium, Federal. Circuit, appeal
